• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Knight Therapeutics

Alimera Sciences wins Health Canada nod for diabetic macular edema implant

December 5, 2018 By Sarah Faulkner

Alimera Scienes updated logo

Alimera Sciences (NSDQ:ALIM) said last month that it won approval in Canada for its intravitreal implant designed to treat diabetic macular edema. The Iluvien device is a sustained release implant that delivers fluocinolone acetonide and is indicated to treat diabetic macular edema in people who have been previously given corticosteroids and did not have a […]

Filed Under: Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, Knight Therapeutics

Braeburn, Knight seek Health Canada nod for opioid dependence implant

June 13, 2017 By Sarah Faulkner

Braeburn Pharmaceuticals

Braeburn Pharmaceuticals and Knight Therapeutics (TSE:GUD) said today that Health Canada has agreed to review Knight’s new drug submission for Probuphine, a buprenorphine subdermal implant designed to treat opioid drug dependence. In February last year, Braeburn and Knight inked an exclusive distribution and sublicense deal, giving Knight the exclusive right to distribute Probuphine in Canada. Braeburn’s […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pain Management, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Braeburn Pharmaceuticals, Knight Therapeutics

Alimera, Brill Pharma ink exclusive distribution deal for Iluvien intravitreal implant

March 13, 2017 By Sarah Faulkner

Alimera Sciences (NSDQ:ALIM) said today that it inked an exclusive distribution deal with Spain-based Brill Pharma for its Iluvien sustained-release intravitreal implant. According to the agreement, Brill Pharma will promote, market and commercialize the diabetic macular edema implant in Spain. It will also negotiate with the Spanish Ministry of Health on the implant’s public price and […]

Filed Under: Featured, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: Alimera Sciences, Brill Pharma, Knight Therapeutics

Alimera, Knight seek Canadian regulatory nod for Iluvien intravitreal implant

February 22, 2017 By Sarah Faulkner

Alimera, Knight seek Canadian regulatory nod for Iluvien intravitreal implant

Alimera Sciences (NSDQ:ALIM) and Knight Therapeutics (TSE:GUD) said today that Health Canada accepted the companies’ New Drug Application for its intravitreal implant, Iluvien. The FDA approved Atlanta-based Alimera’s sustained release intravitreal implant in 2014 to treat diabetic macular edema in patients who have been previously treated with corticosteroids and did not have a clinically significant rise in […]

Filed Under: Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic, Regulatory/Compliance, Wall Street Beat Tagged With: Alimera Sciences, Knight Therapeutics

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS